Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1

Conditions

Small Cell Lung Carcinoma 1Ovarian Neoplasms 1Lung Neoplasms 1

Interventions

pembrolizumab 18Nivolumab 7Carboplatin 7durvalumab 5Ipilimumab 5aldesleukin 4Paclitaxel 4Irinotecan 4Gemcitabine 4Docetaxel 4Cisplatin 4sargramostim 3atezolizumab 3Topotecan 3Polymerase Chain Reaction 3Magnetic Resonance Spectroscopy 3temsirolimus 2talazoparib 2carfilzomib 2cabozantinib 2budigalimab 2Trastuzumab 2Therapeutics 2Taxes 2Specimen Handling 2Psychiatric Rehabilitation 2Injections 2Gene Expression Profiling 2Fulvestrant 2Fluorodeoxyglucose F18 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × LCL161 × Gynecologic × Clear all
NCT02649673 2023-12-05

LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies

SCRI Development Innovations, LLC

Phase 1 Terminated
34 enrolled
GynecologicThoracic

Lung Neoplasms, Ovarian Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡